Direct comparison
IRB vs. IBC: What's the Difference?
IRB reviews human-subjects risk under the Common Rule; IBC reviews rDNA biosafety under NIH Guidelines. Compared side by side, plus when a study needs both.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about IRB vs. IBC: What's the Difference?
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do IRB, IBC compare side by side?
The table below compares IRB, IBC across 7 procurement-relevant dimensions, from what it protects through institution-wide trigger.
Side-by-side comparison
| Dimension | IRB | IBC |
|---|---|---|
| What it protects | Rights and welfare of human research subjects | Lab workers, community, and environment from biohazards |
| Regulatory basis | Common Rule (45 CFR 46); 21 CFR Part 56 for FDA-regulated research | NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules |
| Administering federal office | HHS Office for Human Research Protections (OHRP); FDA for regulated products | NIH Office of Science Policy (OSP) |
| What triggers review | Research (45 CFR 46.102(l)) involving a human subject (45 CFR 46.102(e)) — both conditions required | Use of recombinant/synthetic nucleic acid molecules; most institutions also cover other biohazards by local policy |
| Minimum composition | Majority present at convened meeting, including at least one non-scientist member | At least 5 members with rDNA/containment expertise, including at least 2 unaffiliated community representatives |
| What approval authorizes | Enrollment of human subjects under an approved protocol and consent process | Specific biosafety-level (BSL) procedures under an approved risk-category review |
| Institution-wide trigger | Registration and FWA required per institution operating an IRB for covered research | Once any NIH funding applies to rDNA research, Guidelines apply institution-wide to ALL rDNA work regardless of individual project funding |
Common questions
Common questions about IRB vs IBC
Can the same study need only one of the two committees?
+
Yes. Most studies trigger only one — a survey study needs only IRB review, a non-human bench rDNA experiment needs only IBC review. Overlap arises only when a protocol independently meets both committees' triggers.
Does IBC review require the specific project to be NIH-funded?
+
No. Once an institution receives any NIH funding for recombinant/synthetic nucleic acid molecule research, the NIH Guidelines and IBC review apply institution-wide to all such research, regardless of that project's own funding source.
Which committee assigns the biosafety level?
+
The IBC, through risk-category review of the specific agent, procedure, and volume — not the IRB, even on studies that also require IRB approval.
Is an IBC the same thing as an IACUC?
+
No. An Institutional Animal Care and Use Committee (IACUC) reviews the welfare of live vertebrate animals used in research, under a different statutory basis (the Animal Welfare Act and PHS Policy). A study can require IACUC and IBC review together — for example, an animal study using a recombinant viral vector — on the same logic that a human study can require IRB and IBC review together.
